• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Entrectinib in Two Pediatric Patients With Inflammatory Myofibroblastic Tumors Harboring or Gene Fusions.恩曲替尼治疗两名患有携带NTRK或ROS1基因融合的炎性肌纤维母细胞瘤的儿科患者。
JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00095. Epub 2018 Sep 13.
2
Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors.ROS1的表达可预测炎性肌纤维母细胞瘤中的ROS1基因重排。
Mod Pathol. 2015 May;28(5):732-9. doi: 10.1038/modpathol.2014.165. Epub 2015 Jan 23.
3
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).恩曲替尼在儿童和青少年伴有 NTRK、ROS1 或 ALK 异常的实体或原发性中枢神经系统肿瘤患者中的疗效（STARTRK-NG）。
Neuro Oncol. 2022 Oct 3;24(10):1776-1789. doi: 10.1093/neuonc/noac087.
4
Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.具有频繁间变性淋巴瘤激酶（ALK）和ROS1基因融合以及罕见新型RET重排的炎性肌纤维母细胞瘤的分子特征
Am J Surg Pathol. 2015 Jul;39(7):957-67. doi: 10.1097/PAS.0000000000000404.
5
Uterine inflammatory myofibroblastic tumor harboring novel NUDCD3-ROS1 and NRP2-ALK fusions: clinicopathologic features of 4 cases and literature review.子宫炎性肌纤维母细胞瘤伴有新型 NUDCD3-ROS1 和 NRP2-ALK 融合：4 例临床病理特征及文献复习。
Virchows Arch. 2023 Mar;482(3):567-580. doi: 10.1007/s00428-022-03457-7. Epub 2023 Jan 10.
6
Acral Lentiginous Melanoma Harboring a Gene Fusion With Clinical Response to Entrectinib.伴有与恩曲替尼临床反应相关基因融合的肢端雀斑样痣黑色素瘤
JCO Precis Oncol. 2017 Nov;1:1-7. doi: 10.1200/PO.16.00013.
7
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).多靶点泛TRK、ROS1和ALK抑制剂恩曲替尼的安全性和抗肿瘤活性：两项I期试验（ALKA-372-001和STARTRK-1）的联合结果
Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9.
8
Uterine Inflammatory Myofibroblastic Tumors Frequently Harbor ALK Fusions With IGFBP5 and THBS1.子宫炎性肌纤维母细胞瘤常携带 ALK 融合基因，与 IGFBP5 和 THBS1 相关。
Am J Surg Pathol. 2017 Jun;41(6):773-780. doi: 10.1097/PAS.0000000000000801.
9
Gene rearrangements in consecutive series of pediatric inflammatory myofibroblastic tumors.连续系列小儿炎性肌纤维母细胞瘤中的基因重排。
Pediatr Blood Cancer. 2020 May;67(5):e28220. doi: 10.1002/pbc.28220. Epub 2020 Feb 16.
10
Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.恩曲替尼治疗转移性 NSCLC：安全性和疗效。
Expert Rev Anticancer Ther. 2020 May;20(5):333-341. doi: 10.1080/14737140.2020.1747439. Epub 2020 Apr 8.

引用本文的文献

1
Reclassification of a spindle cell sarcoma after identification of a TFG-ROS1 fusion: A case demonstrating the clinical benefit of next-generation sequencing in sarcoma.TFG-ROS1 融合基因鉴定后 spindle 细胞肉瘤的重新分类：一项展示下一代测序在肉瘤中临床获益的病例。
Mol Genet Genomic Med. 2024 Apr;12(4):e2423. doi: 10.1002/mgg3.2423.
2
Individualized targeted treatment in a case of a rare TFG::ROS1 fusion positive inflammatory myofibroblastic tumor (IMT).一例罕见的TFG::ROS1融合阳性炎性肌纤维母细胞瘤（IMT）的个体化靶向治疗。
Cancer Rep (Hoboken). 2024 Jan;7(1):e1916. doi: 10.1002/cnr2.1916. Epub 2023 Nov 11.
3
[Receptor tyrosine kinase- fusions in paediatric spindle cell tumors].[儿童梭形细胞肿瘤中的受体酪氨酸激酶融合]
Pathologie (Heidelb). 2023 Nov;44(6):357-365. doi: 10.1007/s00292-023-01228-y. Epub 2023 Oct 11.
4
Locally Advanced Inflammatory Myofibroblastic Tumor Treated With Targeted Therapy: A Case Report and Literature Review.局部晚期炎性肌纤维母细胞瘤的靶向治疗：一例报告及文献综述
Cureus. 2022 Jul 25;14(7):e27223. doi: 10.7759/cureus.27223. eCollection 2022 Jul.
5
Molecular Targets for Novel Therapeutics in Pediatric Fusion-Positive Non-CNS Solid Tumors.小儿融合基因阳性非中枢神经系统实体瘤新型治疗药物的分子靶点
Front Pharmacol. 2022 Jan 20;12:747895. doi: 10.3389/fphar.2021.747895. eCollection 2021.
6
Outstanding Response in a Patient With ROS1-Rearranged Inflammatory Myofibroblastic Tumor of Soft Tissues Treated With Crizotinib: Case Report.克唑替尼治疗ROS1重排的软组织炎性肌纤维母细胞瘤患者的显著反应：病例报告
Front Oncol. 2021 Jun 15;11:658327. doi: 10.3389/fonc.2021.658327. eCollection 2021.
7
Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor.病例报告：循环肿瘤细胞作为ALK阳性转移性炎性肌纤维母细胞瘤的反应生物标志物
Front Pediatr. 2021 Apr 29;9:652583. doi: 10.3389/fped.2021.652583. eCollection 2021.
8
ROS1-dependent cancers - biology, diagnostics and therapeutics.ROS1 依赖性癌症——生物学、诊断学与治疗学。
Nat Rev Clin Oncol. 2021 Jan;18(1):35-55. doi: 10.1038/s41571-020-0408-9. Epub 2020 Aug 5.

本文引用的文献

1
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic Fusion-Positive Non-Small-Cell Lung Cancer.恩曲替尼治疗局部晚期或转移性融合阳性非小细胞肺癌的疗效与安全性的最新综合分析
J Clin Oncol. 2021 Apr 10;39(11):1253-1263. doi: 10.1200/JCO.20.03025. Epub 2021 Mar 1.
2
Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor.神经胶质神经元肿瘤中靶向BCAN-NTRK1融合后的临床和影像学反应
NPJ Precis Oncol. 2017 Mar 20;1(1):5. doi: 10.1038/s41698-017-0009-y. eCollection 2017.
3
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.软组织肉瘤，2.2018 年版，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2018 May;16(5):536-563. doi: 10.6004/jnccn.2018.0025.
4
Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene.具有间变性淋巴瘤激酶融合基因的炎性肌成纤维细胞瘤对艾乐替尼产生显著反应。
Jpn J Clin Oncol. 2017 Dec 1;47(12):1189-1192. doi: 10.1093/jjco/hyx133.
5
Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches.采用下一代测序方法检测肺癌患者中的已知和新型 ALK 融合转录本。
Sci Rep. 2017 Oct 2;7(1):12510. doi: 10.1038/s41598-017-12679-8.
6
Recent Advances in Targeting ROS1 in Lung Cancer.ROS1 靶向治疗肺癌的最新进展。
J Thorac Oncol. 2017 Nov;12(11):1611-1625. doi: 10.1016/j.jtho.2017.08.002. Epub 2017 Aug 14.
7
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.从10000例患者的前瞻性临床测序中揭示的转移性癌症的突变图谱。
Nat Med. 2017 Jun;23(6):703-713. doi: 10.1038/nm.4333. Epub 2017 May 8.
8
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).多靶点泛TRK、ROS1和ALK抑制剂恩曲替尼的安全性和抗肿瘤活性：两项I期试验（ALKA-372-001和STARTRK-1）的联合结果
Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9.
9
Novel exon-exon breakpoint in fusion sarcoma identified by anchored multiplex PCR (Archer FusionPlex Sarcoma Panel).通过锚定多重PCR（阿彻融合基因检测肉瘤试剂盒）鉴定出融合肉瘤中的新型外显子-外显子断点。
J Clin Pathol. 2017 Aug;70(8):697-701. doi: 10.1136/jclinpath-2016-204247. Epub 2017 Jan 30.
10
Identification of NTRK fusions in pediatric mesenchymal tumors.小儿间叶组织肿瘤中NTRK融合基因的鉴定
Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26433. Epub 2017 Jan 18.

Entrectinib in Two Pediatric Patients With Inflammatory Myofibroblastic Tumors Harboring or Gene Fusions.

作者信息

Ambati Srikanth R, Slotkin Emily K, Chow-Maneval Edna, Basu Ellen M

机构信息

Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Ignyta, Inc., San Diego, CA, USA.

出版信息

JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00095. Epub 2018 Sep 13.

DOI:10.1200/PO.18.00095
PMID:31763577
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6874363/
Abstract
摘要